Kornimate/medical-research-clean huggingface dataset:
accuracy of pulse oximeters with profound hypoxia

Conditions: SpO2

Summary: this project aims to test the accuracy of pulse oximeters during mild, moderate, and severe hypoxia, i.e., a range of arterial hbo2 saturation from 100 down to 70%. a typical study will include at least ten subjects (at least 200 necessary data points to meet the iso 80601-2-61:2017).

after local anesthetic injection, a 22-gauge catheter is inserted in one radial artery. pulse oximeters are attached to fingers, ears, or flat body surfaces. subjects are in a comfortable semi-recumbent position. subjects then breathe air mixtures containing reduced amounts of oxygen to produce the desired level of hypoxemia. stable, safe, and controlled hypoxia is breath-by-breath by breath respiratory gas analysis and a computer program that permits the inspired gas mixture to be adjusted to achieve a level of lung alveolar gas that will achieve the desired degree of saturation.

Eligibility criteria:
inclusion criteria: 1. the subject is male or female, aged ≥18 and \<50. 2. the subject is in good general health with no evidence of any medical problems. 3. the subject is fluent in both written and spoken english. 4. the subject has provided informed consent and is willing to comply with the study procedures. exclusion criteria: 1. the subject is obese (bmi\>30). 2. the subject has a known history of heart disease, lung disease, kidney or liver disease. 3. diagnosis of asthma, sleep apnea, or use of cpap. 4. subject has diabetes. 5. subject has a clotting disorder.
effects of exercises on total body health in children with acute lymphoblastic leukemia

Conditions: Acute Lymphoblastic Leukemia; Bone Density Increased

Summary: in recent years, the survival of patients has increased with the success of leukemia treatment in children. however, according to the treatment modalities applied, complications such as changes in body composition such as obesity, osteoporosis and impaired bone health such as increased fragility are more frequent after treatment in patients.in this study, virtual reality exercise practices in remission of acute lymphoblastic leukemia cases will prevent negative effects on bone health and body composition and increase the quality of life of patients.

treatment and intervention options are being tried to avoid such complications that affect the quality of life of patients and there is still no standard treatment to convert bone health to healthy bone structure before the disease. there is a positive effect of improving the bone health of the activity and exercise programs. in this study, it was planned to demonstrate the positive effects of these changes on bone health through changes of adipokines and myokins released from fat and muscle tissue by virtual reality exercise method. thus, the quality of life can be increased and cancer complications can be reduced in cancer cases.

Eligibility criteria:
inclusion criteria: * treatment for acute lymphoblastic leukemia * at remitted term * being between 3 and 18 years * healthy cases of age and gender control group cases exclusion criteria: * smaller than 3 years old and older than 18 years old * having a chronic illness * any drug use * any developmental anomaly

Keywords: acute lymphoblastic leukemia bone density total fat exercise
cyclosporine a in the treatment of juvenile idiopathic arthritis (jia) associated chronic anterior uveitis

Conditions: Uveitis; Juvenile Idiopathic Arthritis

Summary: juvenile idiopathic arthritis (jia) is often associated with chronic anterior uveitis. presence of vision threatening complications may indicate immunosuppressive therapy. in this study, the experience with cyclosporine a (csa) as mono- or combination-therapy is analyzed.


Eligibility criteria:
inclusion criteria: * uveitis * jia

Keywords: uveitis jia cyclosporine a mtx
neoadjuvant therapy in cervical cancer

Conditions: Uterine Cervical Neoplasms

Summary: in the comprehensive dataset of clinical diagnoses and treatments for cervical cancer in china, 49.8% of patients with stage ib3 and iia2 receive surgical intervention following neoadjuvant chemotherapy. this indicates a pressing need to optimize neoadjuvant chemotherapy regimens for locally advanced cervical cancer. while paclitaxel combined with cisplatin is the conventional approach, 9.8% to 30.6% of patients demonstrate suboptimal responses, with a pathological complete response rate of approximately 10%. currently, the efficacy of antibody-drug conjugates in neoadjuvant chemotherapy for cervical cancer remains unexplored. this study seeks to address this gap by evaluating the combination of disitamab vedotin and cisplatin in patients with stage ib3 and iia2 cervical cancer with positive her2 expression.the study will assess the impact of this regimen on pathological complete response rates, surgical complications, surgical resection rates, and overall survival.

primary research objectives: to evaluate the effect of disitamab vedotin combined with cisplatin on pathological response rate (pcr) of locally advanced cervical cancer. secondary research objectives: 1. to evaluate the safety of disitamab vedotin combined with cisplatin; 2. to evaluate the effects of disitamab vedotin combined with cisplatin on surgical complications, surgical clearance rate and postoperative adjuvant treatment ratio; 3. to evaluate the effects of disitamab vedotin combined with cisplatin on objective tumor response rate (orr), disease control rate (dcr) and survival; exploratory research objectives: to explore the changes of tumor tissue protein expression, immune factors and her-2 receptor expression before and after the use of adc drugs, as well as biomarkers that can effectively predict the therapeutic effect.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of cervical squamous cell carcinoma * her-2 positive exclusion criteria: * cervical adenocarcinoma
diet induced ketosis for patients with posttraumatic stress disorder (ptsd), a feasibility study

Conditions: PTSD; Post Traumatic Stress Disorder

Summary: many patients suffering from posttraumatic stress disorder (ptsd) are resistant to established treatment consisting of psychotherapy. patients often go years with this debilitating disorder without experiencing sufficient improvement. approximately 1/3 of patients will drop out of treatment because of psychological burden and overactivation. a novel ketogenic diet treatment could amend established treatment, and potentially upregulate the threshold for exciting neurons in dysfunctional brain regions, mediated through various mechanisms. this may reduce ptsd symptoms, and thus enabling patients to respond to psychological treatment without getting overactivated and unable to process trauma. the purpose of this study is to investigate whether it is possible to carry out a ketogenic diet therapy for patients with ptsd for four weeks.

the study aims to include 10 ptsd patients. if a participant drops out of the study, or if the study is otherwise terminated for a participant, another patient will be recruited until 10 have completed the study. the primary objectives of this feasibility study are to investigate if it is possbile to carry out a ketogenic diet therapy for patients with ptsd for 4 weeks, and systematically gain insight in all challenges relating to these objectives. the participants will follow a ketogenic diet for 4 weeks, and they are asked to self report daily on results from finger pricking blood measurements (glucose and betahydroxybutyrate (bhb)) to establish they are in a ketogenic state and are compliant to diet. participants will also report food intake and side effects daily to be evaluated by the principal investigator. participants are further asked to specify and elaborate on which adverse effects or other reasons as to why it is challenging to follow the study diet and/or procedures. the study lacks in power to statistically evaluate if ketosis has any effect on ptsd symptoms, however this secondary objective will be preliminary evaluated.

Eligibility criteria:
inclusion criteria: * patients 18-65 years * diagnosed with posttraumatic stress disorder (ptsd) * understand and speak scandinavian language exclusion criteria: * body mass index \< 18 * metabolic disorders contraindicating a ketogenic diet * dysregulated diabetes mellitus * medicated for elevated triglycerides * pancreas, kidney or liver disorders
tdcs-augmented exposure therapy for pathological fear

Conditions: Specific Phobias

Summary: this double-blind randomized controlled clinical trial aims to test whether transcranial direct current stimulation (tdcs) can be used to modulate fear extinction learning during exposure therapy for pathological fear, including fear of spiders, snakes, or germs / contamination. participation takes place over three laboratory visits, including (1) a pre-treatment visit, (2) a treatment and post-treatment visit, and (3) a 1 month follow-up visit. during treatment, participants will receive either 20 minutes of active or sham tdcs, followed by 30 minutes of in vivo exposure therapy.

in a trans-diagnostic sample with marked pathological fear and behavioral avoidance, this study aims to: (1) evaluate whether excitatory tdcs of the mpfc and inhibitory tdcs of right dlpfc enhances exposure therapy relative to sham tdcs; (2) determine whether tdcs effects are moderated by baseline negative prognostic indicators; and (3) determine whether tdcs effects are mediated by pre-post changes in vigilance to threat, in-session fear reduction, and contextual memory for the exposure context. if successful, the project may discover a potentially effective exposure therapy augmentation, and may enhance knowledge of the behavioral, cognitive, affective, and neurobiological factors that moderate and mediate acute treatment response and maintenance of treatment gains. this knowledge may inform treatment development efforts for more debilitating forms of pathological fear.

Eligibility criteria:
inclusion criteria: 1. age 18-65. 2. fluent in english. 3. a score on at least 1 fear domain-specific prescreen measure \> 2 sds above the subject pool prescreen mean. these measures include (a) fsq, and (b) oci-r. 4. peak fear ≥ 50 on bats 1 and 2. exclusion criteria: 1. currently receiving treatment for the primary fear domain (based on clinical interview). 2. unstable dose of psychotropic medications within 6 weeks prior to baseline assessment (based on the dmq; see measures). 3. medical condition that would contraindicate participation in treatment or assessment activities (e.g., cardiovascular problems; based on the dmq; see measures). 4. pregnancy (based on the dmq; see measures). 5. current major depressive disorder (based on mini; see measures). 6. current, or history of bipolar disorder (based on mini; see measures). 7. current, or history of psychotic symptoms (based on mini; see measures). 8. serious suicidal risk, as determined by self-report (c-ssrs, bdi-ii) and clinical interview (mini; see measures). 9. active neurological conditions, including seizures, stroke, unexplained loss of consciousness or concussion (based on dmq and tdcs safety screening form; see measures) 10. contraindications for tdcs: metal in the head or implanted brain medical devices.

Keywords: arachnophobia (fear of spiders) ophidophobia (fear of snakes) germaphobia (fear of germs, dirtiness, and contamination)
vitamin d, cardiac surgery and outcome

Conditions: Cardiovascular Disease

Summary: we will use a retrospective data analysis to evaluate the association of vitamin d status with clinical outcome in cardiac surgical patients. the occurrence of several postoperative adverse events such as myocardial infarction, low cardiac output syndrome, stroke and in-hospital death will be assessed from cardiac surgery to discharge. in addition, we will assess the association of vitamin d status with the duration of mechanical ventilatory support and intensive care unit stay from cardiac surgery to discharge. moreover, in-hospital stay will be assessed according to vitamin d status.

in a retrospective data analysis, we will evaluate the association of vitamin d status (circulating 25-hydroxyvitamin d) with macce (major cardiac or cerebrovascular event) in cardiac surgical patients. the occurrence of several postoperative adverse events such as myocardial infarction, low cardiac output syndrome, stroke and in-hospital death will be assessed from cardiac surgery to discharge. approximately 4,500 data sets from january 2010 until the end of 2011 will be analyzed.in all patients, we will also assess the association of vitamin d status with the duration of mechanical ventilatory support and intensive care unit stay from cardiac surgery to discharge. moreover, in-hospital stay will be assessed according to vitamin d status.

Eligibility criteria:
inclusion criteria: * cardiac surgical patients aged 18 years and older exclusion criteria: * age \< 18 years * heart transplant recipients * pacemaker or defibrillator implantation

Keywords: vitamin d 25-hydroxyvitamin d macce mortality cardiac cerebrovascular
a safety and efficacy study of squalamine lactate for injection (msi-1256f) for "wet" age-related macular degeneration

Conditions: "Wet" Age-Related Macular Degeneration

Summary: age-related macular degeneration (amd) is a degenerative eye disease of the retina that causes a progressive loss of central vision. amd is the leading cause of blindness among adults age 50 or older in the western world. amd presents in two different types: "dry" and the more severe "wet" form. wet amd is caused by the growth of abnormal blood vessels in the macula. squalamine lactate is an investigational drug that may prevent the growth of these abnormal blood vessels. this study will evaluate the safety and efficacy of squalamine lactate in the treatment of amd in patients, the exact number of which will be determined based on data from the sponsor's ongoing phase 2 trials. the trial objective is to evaluate the safety and efficacy of two doses of squalamine lactate for injection administered as intravenous infusions weekly for 4 weeks followed by maintenance doses every 4 weeks through week 104 compared with the safety and efficacy in the control group.


Eligibility criteria:
inclusion criteria: * patients with a diagnosis of "wet" age-related macular degeneration exclusion criteria: * prior treatment for "wet" age-related macular degeneration in the affected eye in the past 3 months

Keywords: wet amd macular degeneration
intraperitoneal techniques of local anaesthesia during laparoscopic cholecystectomy

Conditions: Gall Stones

Summary: pain following laparoscopic cholecystectomy (lc) results in morbidity and is a barrier to same day discharge. in several trials local anaesthetic (la) washed over the liver and gall bladder decreases pain. in many patients pain has a strong component attributable to diaphragmatic origin. a wash of la over the liver and gall bladder is unlikely to provide high levels of analgesia to pain fibres from the diaphragm. the investigators hypothesise that la injected to the right hemidiaphragm during lc would be more effective than wash. methods double blind randomised controlled trial of 128 consecutive subjects undergoing elective lc. control -sham injection of diaphragm and sham wash over liver/gb with saline; test treatment 'subperitoneal la' - bupivocaine injection/sham wash; internal control 'topical la' - sham injection/bupivocaine wash. primary outcome: pain scores in theatre recovery and the ward. secondary outcomes: analgesic use, physiological observations, time to eating and mobilising, day case surgery.


Eligibility criteria:
inclusion criteria: * elective laparoscopic cholecystectomy * 18 years old or over exclusion criteria: * emergency surgery * under 18 year olds

Keywords: local anaesthetic laparoscopic cholecystectomy pain scores bupivocaine day case surgery
evaluation of the composition of human milk and health outcomes in children

Conditions: Respiratory Symptoms; Signs and Symptoms, Digestive; Anemia

Summary: this study is an evaluation of the composition of human milk and health outcomes in children.


Eligibility criteria:
inclusion criteria: * human milk samples from mothers from a larger birth co-hort study * health outcomes of children from mothers from a larger birth co-hort study from birth through two years of age

Keywords: skin symptoms
observation of histological changes in parathyroid adenomas following high intensity focused ultrasound (hifu) treatment procedure

Conditions: Primary Parathyroid Adenomas

Summary: this study is a multicentre, open, uncontrolled trial for the observation of histological changes in parathyroid adenomas following high intensity focused ultrasound (hifu). this study will be conducted in france in 10 patients with primary hyperparathyroidism scheduled for a parathyroidectomy. the patient will receive an hifu treatment in the center of the adenoma before the surgery.


Eligibility criteria:
inclusion criteria: * male or female patient 18 years or older. * patients with diagnosed primary hyperparathyroidism (clinical symptoms and/or biochemical disturbances) scheduled for parathyroidectomy. * one diseased parathyroid gland, visualized by ultrasonography. * the diseased targeted parathyroid gland accessible for hifu treatment (anonymised ultrasonographic images to be sent to the sponsor's technical team for validation). * normal pretreatment nasofibroscopy. * voluntary signed informed consent. exclusion criteria: * inaccessibility or high risk of targeting neighbouring structures, as evidenced by: * targeted area located less than 2 mm laterally from the oesophagus or the carotid artery * targeted area located less than 3 mm laterally from the trachea, * significant hyperechoic area with a posterior shadow located less than 10 mm behind the targeted area (behind to be understood as posterior to the targeted area in the direction of the hifu beam) * investigator appreciation of any abnormal blood test that could contraindicate treatment with hifu (bleeding abnormalities) * known spondylitis of the neck vertebrae * head and/or neck disease that prevents hyperextension of neck. * known history of parathyroid or other neoplasias in the neck region. * history of neck irradiation * patients whose concurrent illnesses, disability, or geographical residence would hamper attendance at required study visit * pregnant or lactating woman. * female patient of childbearing age if not having a suitable contraception method. * patients who have received any investigational drug or device within the last 15 days and/or patients who are currently participating in another clinical trial.

Keywords: primary hyperparathyroidism high intensity focused ultrasound parathyroid tumor parathyroid hormone calcium
fast-track giant ventral hernia repair

Conditions: Hernia, Ventral

Summary: the implementation of an enhanced recovery pathway after giant ventral hernia repair, including preoperative high-dose steroid is examined prospectively and compared with a group of historic controls.

all patients operated on for a large incisional hernia are treated according to the study protocol. patients are given high-dose glucocorticoid preoperative and the aim is to discharge patients at postoperative day 3. morbidity, length of stay, pain, nausea and pulmonary function are among registered outcomes compared with a historic control group.

Eligibility criteria:
inclusion criteria: * horizontal fascia defect \> 10 cm on computed tomography scan * planned elective open incisional hernia repair exclusion criteria: * known allergy against glucocorticoid treatment * insulin-treated diabetes * gastric ulcer diagnosed within four weeks preoperative * steroid-treated immune disease * planned intestinal anastomosis concomitant to hernia repair
radiotherapy vs observation for post chemotherapy residual mass in advanced seminoma

Conditions: Seminoma

Summary: testicular tumors account for 1% of all cancers in males and germ cell tumors comprise 95% of all testicular cancers. seminomas consist of around 50% of cases. however,adequate information is not there as 60- 80% residual disease is seen even after with the standard management of chemotherapy. with the advent of functional imaging there was hope that it could aid in more accurately targeting these tumors to systematically evaluate the role of pet-ct imaging in identifying patients diagnosed with stage iib-iiic seminomatous germ cell tumor, with residual visible tumor post chemotherapy who would benefit with loco regional radiotherapy. the therapeutic research in seminomashas been relatively slow and such structured studies can allow analysis of large number of patients to report on acute and late effect of treatment outcomes using ctcae and qol (eortc qlq c-30) in these cancers. we hope that we will get help in identifying thrust areas for future research through this study.


Eligibility criteria:
inclusion criteria: 1. histological diagnosis of classical seminoma 2. primary site - testis, mediastinum or retroperitoneum 3. stage iib-iiic (ajcc 8th edition) 4. age\>18 years 5. karnofsky performance status at least 70 6. a response assessment fdg petct scan done at least twelve weeks after the first line chemotherapy, showing a persistent measurable residual mass 7. patient willing and reliable for follow up and qol. exclusion criteria: 1. histology other than classical seminoma 2. non completion of planned first-line chemotherapy 3. prior history of radiotherapy to the involved region 4. inability to deliver adequate radiotherapy dose safely based on assessment by radiation oncologist

Keywords: fdg-pet ct, radiotherapy
transcriptomic profile of endometrium in different histological dating of hormone replacement cycle

Conditions: Infertility, Female

Summary: at present, the evaluation criterion of endometrial receptivity is controversial. the development of a molecular diagnostic tool, the endometrial receptivity array (era) for diagnosis of endometrial receptivity . but use of this test in patients with rif has shown that the window of implantation (woi) is displaced in only a quarter of these patients and use of a personalized embryo transfer (pet) on the day designated by era improves reproductive performance with higher cost .what is known to the others'population? the morphological changes observed on histology for each specific day after ovulation were described by noyes and his colleagues in 1950 . an endometrial biopsy that shows a difference of more than 2 days between the histologic dating and actual day after ovulation is considered to be ''out of phase''. but such pet studies according to the noyes criterion in hormone replacement cycle are lacking . the aim of this study is to explore the transcriptomic profile of endometrial receptivity in different histological dating of hormone replacement cycle and its clinical application.


Eligibility criteria:
inclusion criteria: * the inclusion criteria for rif group were: unexplained repeated implantation failure (rif) is defined as the absence of a gestational sac on ultrasound at 5 or more weeks after embryo transfer (et) after 3 embryo transfers with high quality embryos or after the transfer of ≥10 embryos in multiple transfers. the inclusion criteria for control group were: (1) age \ 37 days; (3) baseline follicle- stimulating hormone (fsh) \< 9.0 iu/l; (4) endometrial thickness ≥7.0 mm on the day of hcg administration. exclusion criteria: * the exclusion criteria were: (1) uterine abnormalities (double uterus, bicornuate uterus, unicornuate uterus); (2) intrauterine adhesions（moderate - severe）, endometriosis, adenomyosis, untreated hydrosalpinx, uterine fibroids (submucosal fibroids, nonmucosal fibroids \>4.0 cm and/or endometrial pressure) (3) history of adverse pregnancy (including spontaneous abortion, stillbirth, and fetal malformation).